An observational study in Congestive Heart Failure, Congestive Heart Failure(CHF) and Congestive Heart Failure (CHF), sponsored by Indiana University. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-16.
Sponsored by Indiana University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Heart Failure by Indiana University — 3 open to participants now, 4 under way, none of them phase 3. Heart Failure · Indiana University.
Among the 15 studies in Heart Failure by Indiana University, this one is the only one that started in 2025, is one of 4 observational ones, and was the 15th registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →3 of the 15 studies in Heart Failure by Indiana University are open now, in 1 country. Recruiting first, the newest first:
Indiana University · Sites in United States
Ages 18+
Indiana University · Sites in United States
By country, each count listing its studies:
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 200 across 1,987 observational studies indexed under Heart Failure.
Median enrollment 90 across the 11 interventional studies, 300 across the 3 observational. Of the 10 that completed or were terminated, 5 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
Indiana University is the lead sponsor of 991 studies on the registry; 202 are open to participants now.
Of its 150 completed or terminated interventional studies of FDA-regulated products, 118 (79%) have results posted.
2 of the studies in Heart Failure by Indiana University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05601817Indiana UniversityVirtual Reality and Computerized Cognitive Intervention for Mild Cognitive Impairment in Heart Failure | 2027-03-31 |
| NCT06388226Indiana UniversityLeg Heat Therapy in Heart Failure With Preserved Ejection Fraction | 2027-08-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 15 studies in Heart Failure by Indiana University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Imagine having heart failure, a condition where the heart struggles to pump blood, making daily life hard. People with heart failure often don't feel well and end up going to the hospital a lot. Many of these people could feel better with extra help, but there aren't many programs that offer support beyond usual heart failure treatments. That's where the ADAPT program comes in, which stands for "Advancing Symptom Alleviation with Palliative Treatment." In this program, nurses and social workers call people weekly, helping them manage their toughest symptoms, offering tools to cope with heart failure, and keeping the patients' current doctors involved. We tested this program in a research study with heart failure patients and found that it improved their quality of life and lowered depression, anxiety, and heart failure symptoms. The question now is if the ADAPT program will work in the community, outside of a research setting, so that more people could benefit from it. Specifically, can the ADAPT program work well in new places? Will patients and their families find it helpful? Most importantly, can it help improve the lives of people with heart failure in these new settings? To answer these questions, the study team will work with healthcare providers to 1) ask how to adjust the ADAPT program to work well in various settings (e.g. primary care, heart failure clinic) and 2) use this information to create simple materials and trainings to help them easily provide ADAPT. This will prepare for the next phase of this project to test out the new ADAPT program.
Outpatient clinician or staff member with at least 6 months of experience caring for patients with HF
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
-
Concurrent mixed methods design with rapid qualitative analysis of data from semi-structured interviews, structured clinic observations, and descriptive analysis of surveys. Participants will include clinical providers (e.g. physicians, advanced practice providers, nurses, social workers), staff, and leadership at IU Health. As opposed to traditional qualitative methods, rapid qualitative approaches are commonly used in implementation-focused research to guide real-time implementation processes.13 Findings will identify potential clinical partnership site(s) and inform selection and tailoring of strategies to implement ADAPT in a partner clinical site in the next stage of this project.
Qualitative Themes
Qualitative themes from interviews and clinic observations and descriptive summary statistics (e.g. means, percentages) of barriers and facilitators from pCAT and PCSI surveys.
Time frame: Baseline
Plan to share: Undecided — Qualitative interview data is often identifiable
Started Oct 2025 (actual). Primary completion is estimated for Sep 2028, 35 months after the start.
Of 799 non-industry observational studies under Heart Failure, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 100. This study's planned 35 months is below that.
Counting every sponsor, half of 982 studies reached it within 41 months; a quarter within 23 and three quarters within 89.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.